Toward affordable cancer drugs: Do we need firmer price negotiation, me-too drugs, or a biosimilar silver bullet?

Fundytus, Adam; Sullivan, Richard; Booth, Christopher M

Fundytus, Adam; Sullivan, Richard; Booth, Christopher M.

Affiliation

Fundytus A; Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada; Department of Oncology,(,) Queen's University, Kingston, Canada.
Sullivan R; Institute of Cancer Policy, King's College London, London, United Kingdom.
Booth CM; Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada; Department of Oncology,(,) Queen's University, Kingston, Canada. Electronic address: booth@queensu.ca.

Semin Oncol ; 47(6): 353-354, 2020 12.

Article in En | MEDLINE | ID: mdl-33153752

Subject(s)

Antineoplastic Agents/economics; Fees, Pharmaceutical; Biosimilar Pharmaceuticals/economics; Fees, Pharmaceutical/legislation & jurisprudence; Fees, Pharmaceutical/trends; Humans; Negotiating

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Fees, Pharmaceutical / Antineoplastic Agents Type of study: Health_economic_evaluation Limits: Humans Language: En Journal: Semin Oncol Year: 2020 Document type: Article Affiliation country: Canada

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google